MANUFACTURING Seqirus Manufacturing Manufacturing for Global Markets One of the largest influenza vaccine companies in the world, Seqirus operates state-of-the-art manufacturing facilities in three different continents and a globally integrated supply chain for the timely supply of influenza vaccine to customers around the world. We have one of the most comprehensive influenza vaccine portfolios in the industry, tailored to the needs of health care professionals and their patients. As part of our heritage, in Australia Seqirus plays a unique public health role, continuing a long legacy as the manufacturer and sole supplier of a range of products made for the Australian Government in the National Interest, including snake and spider antivenoms and Q fever vaccine. Manufacturing and supply in numbers We operate advanced production facilities in the US, the UK and Australia, and manufacture influenza vaccine using both egg and cell-based technologies. 1 The only influenza vaccine manufacturing facility in Australia 150 million 6-month capacity for pandemic vaccine doses at our Holly Springs plant Approx 650 Employees at the UK’s largest biotechnology site in Liverpool Our Global Manufacturing Network We’re geographically diverse Seqirus is one of the world’s largest influenza vaccine manufacturers with innovative technologies and differentiated products. Learn more Seqirus first to reach large-scale manufacture of cell-based influenza vaccines The accelerated development of Seqirus’ cell-based manufacturing technology at its state-of-the-art manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just three years. Watch video We’re constantly improving our methods and processes Our technical development laboratories are co-located with our manufacturing facilities. They provide the scientific and technical capability to ensure Seqirus products are the best defense for the world against influenza Learn more Report an Adverse Event To report a suspected side effect or adverse event, please visit our Report an Adverse Event page. Learn more GBR-FLU-0006 February 2021 R&D Innovation is vital to achieving our vision of a world protected by influenza. Learn more Products Our broad range of influenza vaccines meet the needs of different populations around the world. Learn more Quality & Safety We are committed to producing high quality, safe and effective products. Learn more Report an Adverse Event Cookie Policy Privacy Notice Modern Slavery Terms of Use Sitemap © 2021 Seqirus. All rights reserved. Seqirus is a trademark of Seqirus UK Limited or its affiliates. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies